Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceKing of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage biotechnology company developing...
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage biotechnology company developing...
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business UpdateStrategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase...
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesKing of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of DirectorsKing of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant DecisionKing of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand ViewingNEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesKing of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substanceNewly manufactured supply will support upcoming clinical trial in...
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25thCompany Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesKing of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateKey Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply ManufacturingKing of Prussia, Pennsylvania--(Newsfile Corp. - May 7,...
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesKing of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family OfficeRegistration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well...
Life Sciences Virtual Investor Forum Presentations Now Available for Online ViewingNEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing.
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thCompany Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com
